Jinlitai® Made Its Debut in the 10th CSITF and Won the Top 10 Projects Award

On the afternoon of June 14, the award ceremony of the 10th China (Shanghai) International Technology Fair ("CSITF") was successfully held at the Shanghai World Expo Exhibition and Convention Center. The new-generation anti-RANKL monoclonal antibody Jinlitai® developed by CSPC with independent intellectual property rights (generic name: Narlumosbart Injection) won the Top 10 Projects Award for its world-leading technology and promising application prospect, becoming the only innovative pharmaceutical product that was awarded such an honor in this CSITF. CSITF is a state-level international comprehensive exhibition in China in the field of technical trade. It attracts nearly a thousand exhibitors and brings together innovative results from 10 countries and regions around the world. Review by professionals, the Top 10 Projects Award is awarded by CSITF to the current hotspots in technical fields. At the award ceremony, Mr. Zhu Min, Director of the Shanghai Municipal Commission of Commerce and Secretary of the Leading Party Members' Group, awarded the honorary medal.

Jinlitai® is a Class 1 new drug and the first IgG4 subtype human anti-RANKL monoclonal antibody worldwide. It was approved conditionally by the National Medical Products Administration according to the priority review and approval process in September 2023 for the treatment of adult patients with giant cell tumor of bone (GCTB) that is surgically unresectable or those who may develop severe dysfunction after surgical resection.

Research data show that compared with the marketed Denosumab (IgG2 subtype) with the same target, Jinlitai® has the characteristics of higher target affinity, faster onset of action, simpler manufacturing process, and more controllable quality. Based on key clinical data of GCTB, Jinlitai® demonstrates a median time to tumor response of 0.95 months, with a tumor response rate as high as 93%, reflecting an internationally advanced level of therapeutic effect. Currently, Jinlitai® is also being developed simultaneously for indications such as tumor bone metastasis and osteoporosis.

CSPC sees innovation as the driving force behind corporate development. The Group invested 4.83 billion yuan in R&D in 2023 and 1.169 billion yuan in the 1st quarter of 2024. We continue to step up R&D efforts, and have established 5 R&D centers worldwide and 8 cutting-edge innovation technology platforms in mRNA, nano-formulations, nucleic acid drugs, and other fields. Currently, we have 130+ innovative drugs under development.

Jinlitai® won the Top 10 Projects Award after its debut on the CSITF, which represents the full recognition of international technology exchange platforms for this product as well as CSPC's innovation capabilities, R&D strength, and the Group's high-level R&D team. In the future, CSPC will adhere to its innovation and internationalization strategies, with a focus on internationally leading new targets, new technologies, and new fields, and continue to promote drug innovation, thereby contributing to global health.